Many studies have suggested that polymorphisms in xenobiotic-metabolizing enzymes (XME) including phase I enzymes such as CYP1A1, CYP1B1, CYP2A6 and CYP2E1, and phase II enzymes such as GSTM1, GSTT1, GSTP1, and microsomal epoxide hydrolase (EPHX) may confer different risks of susceptibility to cancer [12-20], including ESCC [21-23]. This evidence concerns the gene CYP2A6 and cancer.